{"gene":"APOE","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1988,"finding":"ApoE protein serves as a ligand for LDL receptors and participates in cholesterol and lipid transport among cells; a mutant form defective in LDL receptor binding causes familial type III hyperlipoproteinemia; ApoE is synthesized in liver, brain, spleen, and kidney and participates in cholesterol redistribution and repair responses to tissue injury.","method":"Biochemical characterization, receptor-binding assays, mutant analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 1-2 — foundational biochemical work replicated extensively, multiple orthogonal methods","pmids":["3283935"],"is_preprint":false},{"year":2000,"finding":"ApoE is a multifunctional protein whose three isoforms (E2, E3, E4) differ by single amino acid substitutions with profound functional consequences: apoE2 is associated with type III hyperlipoproteinemia; apoE4 increases risk for atherosclerosis and Alzheimer's disease, impairs neurite outgrowth, and reduces cognitive function; isoform-specific differences in cellular signaling exist.","method":"Isoform-specific functional assays, genetic studies, receptor-binding assays","journal":"Annual review of genomics and human genetics","confidence":"High","confidence_rationale":"Tier 1-2 — strong preponderance of evidence across multiple labs and methods","pmids":["11701639"],"is_preprint":false},{"year":2004,"finding":"ApoE peptides from the N-terminal receptor-binding domain (residues 130-149 and 141-155) bind directly to LRP1 (sLRP domains 2, 3, and 4) with KD values in the 100 nM range; mutation of Lys143 (but not Arg142) reduced binding 10-fold; both peptides also bind heparin, which competes for sLRP binding.","method":"Solution binding assays, surface plasmon resonance, mutagenesis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted binding with SPR and mutagenesis in single rigorous study","pmids":["15182176"],"is_preprint":false},{"year":2004,"finding":"ApoE3 forms a direct complex with ABCA1 in fibroblasts; lipid-free apoE3 inhibits apoA-I binding to ABCA1 (IC50 ~2.5 µg/ml vs 12.3 for reconstituted HDL); ABCA1 lipid translocase activity is required for biogenesis of apoE-containing HDL-sized particles; the ABCA1 Tangier disease mutation C1477R abolished apoE3 binding and apoE3-mediated cholesterol efflux; all apoE isoforms showed similar ABCA1 binding and cholesterol efflux kinetics.","method":"Radioligand competition binding, cholesterol efflux assay, native gel analysis, mutant ABCA1 fibroblasts","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, functional mutant validation","pmids":["14754908"],"is_preprint":false},{"year":1999,"finding":"ApoE3, but not apoE4, protects against excitotoxin-induced and age-dependent neurodegeneration in mouse brain; neuronal expression of apoE3 preserved synaptophysin-positive terminals, MAP2-positive dendrites, and neurofilament-positive axons after kainic acid challenge, whereas apoE4 did not provide this protection.","method":"Transgenic mouse model (NSE-promoter driven human apoE3 or E4 in Apoe-/- background), immunohistochemistry, quantitative morphometry","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — clean genetic model with isoform-specific comparison and multiple neuronal readouts","pmids":["10366621"],"is_preprint":false},{"year":1999,"finding":"Truncated apoE (22 kDa N-terminal thrombin-cleavage fragment) and apoE-derived peptides cause intracellular calcium influx and hippocampal neuron death; these effects involve cell surface receptors and are reduced by receptor-associated protein (RAP) or NMDA receptor antagonist MK-801, and require extracellular calcium; protease inhibitors blocked full-length apoE toxicity but not truncated apoE toxicity, suggesting proteolytic fragments mediate apoE neurotoxicity.","method":"Primary neuron culture, calcium imaging, pharmacological inhibition (RAP, MK-801, calcium chelation), protease inhibitor treatment","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — multiple inhibitor approaches, but mechanism not fully reconstituted","pmids":["10436064"],"is_preprint":false},{"year":2003,"finding":"ApoE3 particles stimulate nitric oxide (NO) release from endothelial cells in an isoform-dependent manner (apoE3 > apoE2 > apoE4); this effect is mediated through tyrosine phosphorylation of apoE receptor 2 (apoER2) and downstream PI3-kinase signaling to activate NO synthase.","method":"Fluorescent NO assay in cultured endothelial cells, PI3-kinase inhibitor treatment, tyrosine phosphorylation analysis of apoER2","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional assay with pharmacological dissection, single lab","pmids":["12681505"],"is_preprint":false},{"year":2005,"finding":"When associated with lipid, apoE4 preferentially binds intermediate aggregated forms of Aβ with higher avidity than apoE2 or apoE3; different Aβ conformations during spontaneous aggregation confer differing binding affinities to the three apoE isoforms.","method":"In vitro binding assays with lipid-associated apoE isoforms and Aβ in various aggregation states","journal":"Sub-cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding assay with isoform comparison, single study","pmids":["15709483"],"is_preprint":false},{"year":2013,"finding":"ApoE and soluble Aβ interact minimally in solution and in human CSF; instead, apoE isoforms regulate sAβ metabolism in astrocytes and brain interstitial fluid by competing with Aβ for LRP1-dependent cellular uptake; this competition mechanism—not direct apoE/Aβ binding in extracellular fluids—accounts for apoE's regulation of Aβ clearance.","method":"Multiple biochemical and analytical techniques (size exclusion chromatography, native PAGE, ELISA), brain Aβ microdialysis in mice with apoE infusions, astrocyte uptake assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods, in vitro and in vivo validation","pmids":["23620513"],"is_preprint":false},{"year":2017,"finding":"The TREM2-APOE signaling pathway drives microglia from a homeostatic to a neurodegenerative phenotype in ALS, MS, and AD models; TREM2 induces APOE signaling after phagocytosis of apoptotic neurons; targeting the TREM2-APOE pathway restored homeostatic microglial signature and prevented neuronal loss; APOE-mediated neurodegenerative microglia lose tolerogenic function.","method":"Mouse models of ALS, MS, AD; single-cell transcriptomics; genetic manipulation (TREM2 KO, APOE KO); phagocytosis assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — multiple disease models, genetic epistasis, replicated across conditions","pmids":["28930663"],"is_preprint":false},{"year":2017,"finding":"ApoE4 exacerbates tau-mediated neurodegeneration independently of Aβ; P301S tau mice on an E4 background have higher brain tau levels, more somatodendritic tau redistribution, greater brain atrophy and neuroinflammation than E2, E3, or apoE-KO backgrounds; E4-expressing microglia have higher innate immune reactivity; co-culturing tau-expressing neurons with E4 glia causes more TNF-α secretion and reduced neuronal viability; apoE absence is protective.","method":"Human ApoE knock-in tau transgenic mice, immunohistochemistry, ELISA, neuron-glia co-culture, recombinant ApoE treatment","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models, in vitro and in vivo validation, isoform series","pmids":["28959956"],"is_preprint":false},{"year":2018,"finding":"APOE4 neurons show increased synapse number and elevated Aβ42 secretion; APOE4 astrocytes display impaired Aβ uptake and cholesterol accumulation; APOE4 microglia-like cells exhibit altered morphologies and reduced Aβ phagocytosis; converting APOE4 to APOE3 in sAD iPSC-derived brain cells attenuates multiple AD-related pathologies.","method":"CRISPR/Cas9 isogenic iPSC lines, transcriptional profiling, Aβ secretion/uptake assays, cholesterol measurement, phagocytosis assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1-2 — isogenic human cell system with multiple orthogonal functional assays","pmids":["29861287"],"is_preprint":false},{"year":2019,"finding":"All human ApoE isoforms attenuate classical complement cascade (CCC) activity via high-affinity binding to activated C1q protein (KD ~140-580 pM); C1q-ApoE complexes form in vivo at sites of complement activation including Aβ plaques, choroid plexus, and atherosclerotic arteries; ApoE-deficient mice show oxidized lipid-driven CCC activation and leukocyte infiltration; siRNA against C5 attenuated disease burden.","method":"In vitro binding assays (surface plasmon resonance/KD measurement), ApoE-deficient mouse model, siRNA knockdown, immunostaining of human tissues","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding measurement with KD, multiple disease models, in vivo validation","pmids":["30692699"],"is_preprint":false},{"year":2020,"finding":"APOE4 leads to blood-brain barrier (BBB) breakdown in the hippocampus and medial temporal lobe independently of Aβ or tau pathology; this is associated with increased activity of the cyclophilin A-MMP9 pathway; CSF levels of soluble PDGFRβ (pericyte injury biomarker) predicted future cognitive decline in APOE4 carriers.","method":"Dynamic contrast-enhanced MRI for BBB permeability, CSF biomarkers (PDGFRβ, cyclophilin A, MMP9), PET amyloid/tau imaging in human subjects","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — direct BBB permeability measurement, mechanistic pathway identified, prospective cognitive outcome","pmids":["32376954"],"is_preprint":false},{"year":2016,"finding":"TREM2 binds directly to APOE (and CLU/APOJ) as identified by unbiased protein microarray screen; binding of apolipoproteins by TREM2 was abolished or reduced by AD-associated TREM2 mutations; TREM2 overexpression enhanced cellular uptake of APOE; Trem2 knockout microglia showed reduced internalization; Aβ bound to APOE is taken up by microglia in a TREM2-dependent fashion.","method":"Protein microarray screen, Co-IP, overexpression and KO cellular assays, human macrophages from TREM2 variant carriers","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — unbiased screen validated by multiple functional assays, human genetic validation","pmids":["27477018"],"is_preprint":false},{"year":2022,"finding":"Increased APOE expression in aged human mesenchymal progenitor cells (MPCs) drives cellular senescence; CRISPR-Cas9 deletion of APOE confers resistance to senescence; mechanistically, excess APOE promotes degradation of nuclear lamina proteins and the heterochromatin-associated protein KAP1 via the autophagy-lysosomal pathway, thereby destabilizing heterochromatin.","method":"Human cellular aging models, CRISPR-Cas9 KO, Western blot, autophagy-lysosomal pathway inhibitors, chromatin analysis","journal":"Nature aging","confidence":"High","confidence_rationale":"Tier 2 — CRISPR KO with mechanistic pathway dissection, multiple aging models","pmids":["37117743"],"is_preprint":false},{"year":2023,"finding":"Mitochondrial dysfunction (genetic or pharmacological disruption of ETC complexes I, III, or IV, or SLC25A transporters) causes up to 49-fold upregulation of APOE transcript, protein, and secretion as part of an inflammatory gene expression program; this was demonstrated across diverse cell types including iPSC-derived human astrocytes; age- and genotype-dependent decline in complex I preceded APOE increases in 5xFAD mouse brain.","method":"Gene editing of ETC components, pharmacological ETC inhibitors, iPSC-derived astrocytes, transcriptomics, ELISA, 5xFAD mouse brain analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological perturbations, diverse cell types, in vivo validation","pmids":["37171075"],"is_preprint":false},{"year":2024,"finding":"Lipidated ApoE2 (lipApoE2) has impaired LDLR binding compared to lipApoE3/E4, which avoids LDLR recycling defects and decreases uptake of cholesteryl esters (CEs) linked to neurodegeneration; in human neurons, ApoE carrying polyunsaturated fatty acid-CEs causes lipofuscinosis in an allelic series (E4 > E3 > E2); lipofuscin increases lysosomal tau fibril accumulation; intrahippocampal injection of PUFA-CE-lipApoE4 induces lipofuscinosis; the protective Christchurch mutation also reduces LDLR binding, phenocopying ApoE2.","method":"iPSC-derived human neurons, LDLR binding assays, lipofuscin quantification, tau fibril uptake assays, intrahippocampal injection in mice, APOE4 mouse brain analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic reconstitution in human neurons, in vivo injection, multiple orthogonal approaches","pmids":["39532095"],"is_preprint":false},{"year":2008,"finding":"APP and apoE receptors share extracellular-binding partners (F-spondin, Reelin) that promote their cell surface presence; both APP and apoE receptors are cleaved at the cell surface by alpha-secretase; their processing is regulated by TIMP-3; endothelial APP phosphorylated at Tyr682 associates with Src tyrosine kinase in apoE-/- and AD brains, and APP mediates monocyte adhesion to brain endothelium.","method":"Immunohistochemistry, Western blot, co-immunoprecipitation (APP-Src), modified Stamper-Woodruff adhesion assay","journal":"Molecular neurobiology / Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP and functional adhesion assay, single lab","pmids":["18415033","19058878"],"is_preprint":false},{"year":2013,"finding":"The full-length two-domain structure of apoE3 was characterized and shown to support communication between the N-terminal and C-terminal domains; a single amino acid difference (Cys112→Arg) between apoE3 and apoE4 propagates structural changes from the N-terminal domain through to the C-terminal domain.","method":"Structural analysis and biophysical characterization of recombinant apoE protein","journal":"Protein science","confidence":"Medium","confidence_rationale":"Tier 1 — structural characterization, but limited functional mutational validation in this paper","pmids":["24115173"],"is_preprint":false}],"current_model":"ApoE is a secreted lipoprotein-associated protein that functions as an LDL receptor ligand for cholesterol/lipid transport; its three isoforms (E2, E3, E4) differ by single amino acid substitutions that produce isoform-specific differences in LDLR/LRP1 binding, ABCA1-mediated lipoprotein particle formation, complement C1q inhibition, endothelial NO signaling via apoER2/PI3K, and in the brain: regulation of Aβ clearance through LRP1 competition, direct TREM2 binding to facilitate microglial Aβ/lipoprotein uptake, tau pathology exacerbation via microglial neuroinflammation, blood-brain barrier integrity through pericyte/cyclophilin A-MMP9 signaling, heterochromatin destabilization driving cellular senescence via autophagy-lysosomal degradation of KAP1 and lamins, endolysosomal lipid pathology through LDLR-mediated cholesteryl ester uptake, and upstream regulation by mitochondrial electron transport chain dysfunction."},"narrative":{"teleology":[{"year":1988,"claim":"Establishing ApoE as an LDL receptor ligand central to lipid transport resolved its core molecular function and linked receptor-binding-defective mutations to familial type III hyperlipoproteinemia.","evidence":"Biochemical receptor-binding assays and mutant analysis in multiple tissues","pmids":["3283935"],"confidence":"High","gaps":["Structural basis of receptor recognition not yet defined","Brain-specific functions uncharacterized","Isoform-specific functional consequences not yet delineated"]},{"year":1999,"claim":"Demonstration that ApoE3, but not ApoE4, protects neurons against excitotoxic and age-dependent neurodegeneration established isoform-specific neuroprotective functions independent of peripheral lipid metabolism.","evidence":"Human apoE isoform knock-in transgenic mice challenged with kainic acid, quantitative morphometry of synapses and dendrites","pmids":["10366621"],"confidence":"High","gaps":["Downstream signaling pathway mediating neuroprotection unknown","Whether truncated apoE fragments contribute to neurotoxicity in vivo not settled","Mechanism by which E4 fails to protect not defined"]},{"year":2000,"claim":"Comprehensive functional characterization of all three isoforms consolidated the framework that single amino acid changes (Cys112Arg, Arg158Cys) produce divergent effects on receptor binding, neurite outgrowth, and disease susceptibility.","evidence":"Isoform-specific functional assays, genetic association studies, receptor-binding assays across multiple labs","pmids":["11701639"],"confidence":"High","gaps":["Atomic-level structural basis for isoform-specific domain interactions unresolved","Isoform-specific signaling cascades not mapped"]},{"year":2004,"claim":"Mapping the LRP1-binding epitope to ApoE residues 130–155 with nanomolar affinity and identifying Lys143 as critical resolved the structural requirements for receptor engagement and heparin competition.","evidence":"Surface plasmon resonance, solution binding assays, and site-directed mutagenesis with soluble LRP domains","pmids":["15182176"],"confidence":"High","gaps":["Full-length ApoE–LRP1 co-structure not available","Relative contribution of LRP1 vs LDLR binding in brain Aβ clearance unknown"]},{"year":2004,"claim":"Discovery that ApoE forms a direct complex with ABCA1 and requires ABCA1 lipid translocase activity for HDL-sized particle biogenesis established the mechanism by which ApoE acquires lipid for functional lipoprotein assembly.","evidence":"Radioligand competition binding, native gel analysis, cholesterol efflux assay, and Tangier disease mutant ABCA1 fibroblasts","pmids":["14754908"],"confidence":"High","gaps":["Stoichiometry and structure of ApoE–ABCA1 complex not defined","Whether ABCA1-dependent lipidation differs by isoform in vivo uncertain"]},{"year":2013,"claim":"Demonstrating that ApoE regulates brain Aβ clearance by competing with Aβ for LRP1-dependent uptake—rather than through direct ApoE–Aβ complexes in extracellular fluid—fundamentally reframed the mechanism of ApoE's role in amyloid pathology.","evidence":"Brain microdialysis with apoE infusions in vivo, astrocyte uptake assays, size-exclusion chromatography of CSF","pmids":["23620513"],"confidence":"High","gaps":["Whether competition mechanism operates equivalently across all brain regions not tested","Quantitative contribution of astrocytes vs microglia to Aβ clearance in this model unclear"]},{"year":2013,"claim":"Structural characterization of full-length apoE3 revealed inter-domain communication such that the single Cys112→Arg change in apoE4 propagates conformational changes to the C-terminal domain, providing a physical basis for isoform-specific differences.","evidence":"Biophysical characterization of recombinant full-length apoE protein","pmids":["24115173"],"confidence":"Medium","gaps":["High-resolution co-crystal with receptors not obtained","Functional validation of proposed domain–domain interaction limited"]},{"year":2016,"claim":"Identification of TREM2 as a direct ApoE receptor on microglia—with AD-associated TREM2 mutations impairing binding—established a new axis linking ApoE to microglial phagocytic function and innate immunity in neurodegenerative disease.","evidence":"Unbiased protein microarray screen, co-IP, TREM2 KO and overexpression cellular assays, human TREM2-variant macrophages","pmids":["27477018"],"confidence":"High","gaps":["ApoE–TREM2 binding interface not structurally resolved","Relative contribution of TREM2-dependent vs LRP1-dependent uptake in microglia not quantified"]},{"year":2017,"claim":"Linking the TREM2–APOE axis to a transcriptional switch from homeostatic to neurodegenerative microglial states across ALS, MS, and AD models generalized ApoE's role in microglial polarization beyond Alzheimer's disease.","evidence":"Single-cell transcriptomics in multiple mouse disease models, TREM2 KO and APOE KO genetic epistasis, phagocytosis assays","pmids":["28930663"],"confidence":"High","gaps":["Whether restoring homeostatic microglial state is therapeutic in humans unknown","Whether ApoE isoforms differentially drive this transcriptional switch not tested in this study"]},{"year":2017,"claim":"Demonstrating that ApoE4 exacerbates tau-mediated neurodegeneration independently of Aβ—through enhanced microglial inflammatory reactivity—decoupled ApoE's pathogenic effects from the amyloid cascade.","evidence":"Human ApoE knock-in × P301S tau transgenic mice, neuron-glia co-culture with isoform-specific glia, TNF-α measurement","pmids":["28959956"],"confidence":"High","gaps":["Molecular mechanism by which ApoE4 enhances microglial TNF-α production not defined","Whether ApoE absence is protective in human tauopathy unknown"]},{"year":2018,"claim":"Using isogenic iPSC-derived neurons, astrocytes, and microglia confirmed cell-type-specific ApoE4 pathologies (increased Aβ secretion, impaired Aβ uptake, cholesterol accumulation) in human cells and showed that CRISPR correction of E4 to E3 rescues these phenotypes.","evidence":"CRISPR/Cas9 isogenic iPSC lines, transcriptional profiling, Aβ secretion/uptake assays, cholesterol measurement, phagocytosis assays","pmids":["29861287"],"confidence":"High","gaps":["Whether E4→E3 correction rescues in vivo brain pathology in humanized models not shown","Mechanism by which E4 increases neuronal synapse number unclear"]},{"year":2019,"claim":"Discovery that all ApoE isoforms bind activated C1q with picomolar affinity and attenuate classical complement cascade activation revealed a previously unrecognized immunomodulatory function of ApoE in both brain and vasculature.","evidence":"Surface plasmon resonance (KD ~140–580 pM), immunostaining of human Aβ plaques and atherosclerotic arteries, ApoE-KO mice with C5 siRNA rescue","pmids":["30692699"],"confidence":"High","gaps":["Whether isoform differences in C1q binding affinity are functionally significant in vivo not resolved","Structural basis of ApoE–C1q interaction unknown"]},{"year":2020,"claim":"Demonstrating that APOE4 causes blood–brain barrier breakdown via the cyclophilin A–MMP9 pericyte pathway independently of Aβ/tau established a vascular mechanism for ApoE4-associated cognitive decline.","evidence":"Dynamic contrast-enhanced MRI for BBB permeability, CSF pericyte-injury biomarkers, PET amyloid/tau imaging in human subjects","pmids":["32376954"],"confidence":"High","gaps":["Direct causal link between pericyte CypA–MMP9 and BBB permeability in humans not interventionally tested","Whether BBB breakdown is reversible with CypA inhibition in E4 carriers unknown"]},{"year":2022,"claim":"Showing that elevated APOE drives cellular senescence by promoting autophagy-lysosomal degradation of nuclear lamins and KAP1, destabilizing heterochromatin, extended ApoE's functional repertoire to chromatin regulation and aging.","evidence":"CRISPR-Cas9 APOE KO in human mesenchymal progenitor cells, autophagy-lysosomal pathway inhibitors, Western blot, chromatin analysis","pmids":["37117743"],"confidence":"High","gaps":["Whether this senescence mechanism operates in neurons or astrocytes not tested","How APOE protein triggers autophagy-lysosomal degradation of nuclear lamina components mechanistically unclear"]},{"year":2023,"claim":"Identification of mitochondrial ETC dysfunction as a potent upstream driver of APOE transcriptional upregulation connected metabolic stress to ApoE-mediated inflammatory and neurodegenerative pathways.","evidence":"Gene editing and pharmacological inhibition of ETC complexes I/III/IV, iPSC-derived astrocytes, transcriptomics, 5xFAD mouse brain analysis","pmids":["37171075"],"confidence":"High","gaps":["Transcription factors and cis-regulatory elements mediating ETC-dependent APOE induction not identified","Whether ETC dysfunction-driven APOE increase is sufficient to trigger downstream Aβ or senescence phenotypes not shown"]},{"year":2024,"claim":"Reconstituting ApoE isoform- and LDLR-dependent endolysosomal lipofuscinosis in human neurons—showing that PUFA-cholesteryl ester-loaded ApoE4 particles cause lipofuscin accumulation that enhances tau fibril retention—unified lipid metabolism and tau pathology in a single endolysosomal mechanism.","evidence":"iPSC-derived neurons, LDLR binding assays, lipofuscin quantification, tau fibril uptake, intrahippocampal injection in mice, Christchurch mutation analysis","pmids":["39532095"],"confidence":"High","gaps":["Whether lipofuscinosis pathway is reversible or druggable not tested","Relative contribution of LDLR vs LRP1 in neuronal lipofuscin accumulation not dissected"]},{"year":null,"claim":"Key unresolved questions include the full structural basis of ApoE isoform–receptor complexes, whether therapeutic modulation of TREM2–ApoE or CypA–MMP9 pathways can reverse ApoE4-driven pathology in humans, and the transcriptional mechanism linking mitochondrial dysfunction to APOE upregulation.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution co-crystal structure of ApoE with any receptor","No interventional human trial targeting ApoE-specific pathogenic mechanisms","Transcriptional regulation of APOE by mitochondrial stress not mechanistically dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,3,7,17]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,2,6,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,12,15]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,3,8,12,17]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[15,17]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,3,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,10,12]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,10,11,13,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,9,14]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[15,16]}],"complexes":[],"partners":["LDLR","LRP1","ABCA1","TREM2","C1Q","LRP8"],"other_free_text":[]},"mechanistic_narrative":"Apolipoprotein E is a secreted lipid-transport protein that serves as a high-affinity ligand for the LDL receptor family (LDLR, LRP1, apoER2), mediating cellular cholesterol uptake and redistribution, and whose three common isoforms (E2, E3, E4) differ by single amino acid substitutions that profoundly alter receptor-binding affinity, lipoprotein particle formation via ABCA1, and disease risk [PMID:3283935, PMID:11701639, PMID:14754908]. In the brain, ApoE regulates amyloid-β clearance by competing with Aβ for LRP1-dependent uptake, serves as a direct ligand for the microglial receptor TREM2 to facilitate Aβ/lipoprotein phagocytosis, and exacerbates tau-mediated neurodegeneration through isoform-dependent microglial neuroinflammation, with ApoE4 consistently conferring the greatest pathological burden [PMID:23620513, PMID:27477018, PMID:28930663, PMID:29861287, PMID:28959956]. ApoE4 also disrupts blood–brain barrier integrity through the cyclophilin A–MMP9 pericyte-injury pathway, promotes endolysosomal lipofuscinosis via LDLR-mediated uptake of polyunsaturated fatty acid–cholesteryl esters that enhance lysosomal tau fibril accumulation, and attenuates classical complement activation through picomolar-affinity binding to activated C1q [PMID:32376954, PMID:39532095, PMID:30692699]. Beyond neurodegeneration, elevated APOE expression driven by mitochondrial electron-transport-chain dysfunction promotes cellular senescence by triggering autophagy-lysosomal degradation of nuclear lamina proteins and heterochromatin factor KAP1 [PMID:37117743, PMID:37171075]."},"prefetch_data":{"uniprot":{"accession":"P02649","full_name":"Apolipoprotein E","aliases":[],"length_aa":317,"mass_kda":36.2,"function":"APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:14754908, PubMed:1911868, PubMed:1917954, PubMed:23620513, PubMed:2762297, PubMed:6860692, PubMed:9395455). Apolipoproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:2762297, PubMed:6860692, PubMed:9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:1911868, PubMed:6860692). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:12950167, PubMed:1530612, PubMed:1917954, PubMed:20030366, PubMed:20303980, PubMed:2063194, PubMed:2762297, PubMed:7635945, PubMed:7768901, PubMed:8756331, PubMed:8939961). Finally, APOE also has a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:23676495, PubMed:7635945, PubMed:9395455, PubMed:9488694). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:23676495, PubMed:29516132, PubMed:9395455). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:2762297, PubMed:29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:1917954, PubMed:2762297, PubMed:29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:14754908, PubMed:23620513, PubMed:9395455). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:25173806, PubMed:8939961). APOE is also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). Binds to the immune cell receptor LILRB4 (PubMed:30333625). APOE may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:28111074) (Microbial infection) Through its interaction with HCV envelope glycoprotein E2, participates in the attachment of HCV to HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface and to the assembly, maturation and infectivity of HCV viral particles (PubMed:25122793, PubMed:29695434). This interaction is probably promoted via the up-regulation of cellular autophagy by the virus (PubMed:29695434)","subcellular_location":"Secreted; Secreted, extracellular space; Secreted, extracellular space, extracellular matrix; Extracellular vesicle; Endosome, multivesicular body","url":"https://www.uniprot.org/uniprotkb/P02649/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOE","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOE","total_profiled":1310},"omim":[{"mim_id":"619429","title":"TRANSMEMBRANE AND COILED-COIL DOMAIN FAMILY, MEMBER 2; TMCC2","url":"https://www.omim.org/entry/619429"},{"mim_id":"619324","title":"HYPERTRIGLYCERIDEMIA 2; HYTG2","url":"https://www.omim.org/entry/619324"},{"mim_id":"618983","title":"BLOOD GROUP, LEWIS SYSTEM; LE","url":"https://www.omim.org/entry/618983"},{"mim_id":"618666","title":"SITOSTEROLEMIA 2; STSL2","url":"https://www.omim.org/entry/618666"},{"mim_id":"618055","title":"CELLULAR REPRESSOR OF E1A-STIMULATED GENES 1; CREG1","url":"https://www.omim.org/entry/618055"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adrenal gland","ntpm":3391.3},{"tissue":"brain","ntpm":2714.9},{"tissue":"liver","ntpm":6533.9}],"url":"https://www.proteinatlas.org/search/APOE"},"hgnc":{"alias_symbol":[],"prev_symbol":["AD2"]},"alphafold":{"accession":"P02649","domains":[{"cath_id":"1.20.120.20","chopping":"34-207","consensus_level":"high","plddt":86.5056,"start":34,"end":207}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02649","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02649-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02649-F1-predicted_aligned_error_v6.png","plddt_mean":75.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOE","jax_strain_url":"https://www.jax.org/strain/search?query=APOE"},"sequence":{"accession":"P02649","fasta_url":"https://rest.uniprot.org/uniprotkb/P02649.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02649/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02649"}},"corpus_meta":[{"pmid":"23620513","id":"PMC_23620513","title":"ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23620513","citation_count":452,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10366621","id":"PMC_10366621","title":"Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.","date":"1999","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10366621","citation_count":286,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30692699","id":"PMC_30692699","title":"ApoE attenuates unresolvable inflammation by complex formation with activated C1q.","date":"2019","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30692699","citation_count":232,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"922890","id":"PMC_922890","title":"The initiation sites for RNA transcription in Ad2 DNA.","date":"1977","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/922890","citation_count":199,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26884068","id":"PMC_26884068","title":"The role of APOE in cerebrovascular dysfunction.","date":"2016","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/26884068","citation_count":192,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27386935","id":"PMC_27386935","title":"Do the Apoe-/- and Ldlr-/- Mice Yield the Same Insight on Atherogenesis?","date":"2016","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27386935","citation_count":160,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10436064","id":"PMC_10436064","title":"Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity.","date":"1999","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10436064","citation_count":133,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28057414","id":"PMC_28057414","title":"ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease.","date":"2017","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/28057414","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19174369","id":"PMC_19174369","title":"Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.","date":"2009","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19174369","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38906999","id":"PMC_38906999","title":"Multifaceted roles of APOE in Alzheimer disease.","date":"2024","source":"Nature reviews. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38906999","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31938053","id":"PMC_31938053","title":"Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE-/- mice.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31938053","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11597927","id":"PMC_11597927","title":"Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice.","date":"2001","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11597927","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31911114","id":"PMC_31911114","title":"APOE in the normal brain.","date":"2020","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/31911114","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14754908","id":"PMC_14754908","title":"Molecular interactions between apoE and ABCA1: impact on apoE lipidation.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/14754908","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26980204","id":"PMC_26980204","title":"Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.","date":"2016","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26980204","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23560095","id":"PMC_23560095","title":"BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23560095","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37117743","id":"PMC_37117743","title":"Destabilizing heterochromatin by APOE mediates senescence.","date":"2022","source":"Nature aging","url":"https://pubmed.ncbi.nlm.nih.gov/37117743","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15182176","id":"PMC_15182176","title":"Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)2, bind to LRP1.","date":"2004","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15182176","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29510138","id":"PMC_29510138","title":"AIM2 accelerates the atherosclerotic plaque progressions in ApoE-/- mice.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29510138","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20854809","id":"PMC_20854809","title":"Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression.","date":"2010","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20854809","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28611100","id":"PMC_28611100","title":"AMPK activation enhances the anti-atherogenic effects of high density lipoproteins in apoE-/- mice.","date":"2017","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/28611100","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30232753","id":"PMC_30232753","title":"ApoE and Neurodegenerative Diseases in Aging.","date":"2018","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/30232753","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26169727","id":"PMC_26169727","title":"Endothelial NADPH oxidase 4 protects ApoE-/- mice from atherosclerotic lesions.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26169727","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25784693","id":"PMC_25784693","title":"IL-9 aggravates the development of atherosclerosis in ApoE-/- mice.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/25784693","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"183014","id":"PMC_183014","title":"Conditional lethal mutants of adenovirus type 2-simian virus 40 hybrids. II. Ad2+ND1 host-range mutants that synthesize fragments of the Ad2+ND1 30K protein.","date":"1976","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/183014","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12192621","id":"PMC_12192621","title":"APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.","date":"2002","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12192621","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12681505","id":"PMC_12681505","title":"Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells.","date":"2003","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12681505","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39532095","id":"PMC_39532095","title":"Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39532095","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36888629","id":"PMC_36888629","title":"Butyrate suppresses atherosclerotic inflammation by regulating macrophages and polarization via GPR43/HDAC-miRNAs axis in ApoE-/- mice.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36888629","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24991786","id":"PMC_24991786","title":"Baicalin and geniposide attenuate atherosclerosis involving lipids regulation and immunoregulation in ApoE-/- mice.","date":"2014","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24991786","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26606905","id":"PMC_26606905","title":"High-methionine diets accelerate atherosclerosis by HHcy-mediated FABP4 gene demethylation pathway via DNMT1 in ApoE(-/-) mice.","date":"2015","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/26606905","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1846134","id":"PMC_1846134","title":"Purification and characterization of haloalcohol dehalogenase from Arthrobacter sp. strain AD2.","date":"1991","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/1846134","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28473446","id":"PMC_28473446","title":"Human Plasma Thioredoxin-80 Increases With Age and in ApoE-/- Mice Induces Inflammation, Angiogenesis, and Atherosclerosis.","date":"2017","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/28473446","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10669641","id":"PMC_10669641","title":"Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice.","date":"2000","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10669641","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30630636","id":"PMC_30630636","title":"Geniposide regulates the miR-101/MKP-1/p38 pathway and alleviates atherosclerosis inflammatory injury in ApoE-/- mice.","date":"2018","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30630636","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33241629","id":"PMC_33241629","title":"Acacetin exerts antioxidant potential against atherosclerosis through Nrf2 pathway in apoE-/- Mice.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33241629","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15709483","id":"PMC_15709483","title":"The interaction of amyloid-beta with ApoE.","date":"2005","source":"Sub-cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15709483","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32086626","id":"PMC_32086626","title":"Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice.","date":"2020","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32086626","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30555351","id":"PMC_30555351","title":"Semaphorin 7A Promotes VEGFA/VEGFR2-Mediated Angiogenesis and Intraplaque Neovascularization in ApoE Mice.","date":"2018","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30555351","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31606534","id":"PMC_31606534","title":"Inflammation inhibition and gut microbiota regulation by TSG to combat atherosclerosis in ApoE-/- mice.","date":"2019","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31606534","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29555084","id":"PMC_29555084","title":"AIBP reduces atherosclerosis by promoting reverse cholesterol transport and ameliorating inflammation in apoE-/- mice.","date":"2018","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/29555084","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23603214","id":"PMC_23603214","title":"Mercury, APOE, and children's neurodevelopment.","date":"2013","source":"Neurotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/23603214","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29745836","id":"PMC_29745836","title":"Haplotype analysis of APOE intragenic SNPs.","date":"2018","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29745836","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33262811","id":"PMC_33262811","title":"Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice.","date":"2020","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33262811","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38870781","id":"PMC_38870781","title":"Activation of Nrf2 inhibits atherosclerosis in ApoE-/- mice through suppressing endothelial cell inflammation and lipid peroxidation.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38870781","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33327743","id":"PMC_33327743","title":"TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.","date":"2020","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33327743","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22482072","id":"PMC_22482072","title":"Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.","date":"2012","source":"International journal of Alzheimer's disease","url":"https://pubmed.ncbi.nlm.nih.gov/22482072","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29135917","id":"PMC_29135917","title":"Asperlin Inhibits LPS-Evoked Foam Cell Formation and Prevents Atherosclerosis in ApoE-/- Mice.","date":"2017","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/29135917","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28086184","id":"PMC_28086184","title":"Sex and APOE: A memory advantage in male APOE ε4 carriers in midlife.","date":"2016","source":"Cortex; a journal devoted to the study of the nervous system and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/28086184","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34725437","id":"PMC_34725437","title":"FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE-/- mice atherosclerosis.","date":"2021","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34725437","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21477221","id":"PMC_21477221","title":"Npp1 promotes atherosclerosis in ApoE knockout mice.","date":"2011","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21477221","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33381046","id":"PMC_33381046","title":"Astragalus Flavone Ameliorates Atherosclerosis and Hepatic Steatosis Via Inhibiting Lipid-Disorder and Inflammation in apoE-/- Mice.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33381046","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27374487","id":"PMC_27374487","title":"Betulin attenuates atherosclerosis in apoE-/- mice by up-regulating ABCA1 and ABCG1.","date":"2016","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/27374487","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29605868","id":"PMC_29605868","title":"6-Gingerol Ameliorates Behavioral Changes and Atherosclerotic Lesions in ApoE-/- Mice Exposed to Chronic Mild Stress.","date":"2018","source":"Cardiovascular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29605868","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25488987","id":"PMC_25488987","title":"Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe-/- mice.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25488987","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15246985","id":"PMC_15246985","title":"The role of viruses and of APOE in dementia.","date":"2004","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15246985","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9742120","id":"PMC_9742120","title":"The AD1 and AD2 transactivation domains of E2A are essential for the antiapoptotic activity of the chimeric oncoprotein E2A-HLF.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9742120","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29292046","id":"PMC_29292046","title":"Celosins inhibit atherosclerosis in ApoE-/- mice and promote autophagy flow.","date":"2017","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29292046","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17234687","id":"PMC_17234687","title":"Oxidatively damaged DNA in aging dyslipidemic ApoE-/- and wild-type mice.","date":"2007","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17234687","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24115173","id":"PMC_24115173","title":"Concerning the structure of apoE.","date":"2013","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/24115173","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22662117","id":"PMC_22662117","title":"Ginkgolide B reduces atherogenesis and vascular inflammation in ApoE(-/-) mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22662117","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32047914","id":"PMC_32047914","title":"Protocatechuic Acid Inhibits Vulnerable Atherosclerotic Lesion Progression in Older Apoe-/- Mice.","date":"2020","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/32047914","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30909226","id":"PMC_30909226","title":"Metformin Therapy Aggravates Neurodegenerative Processes in ApoE-/- Mice.","date":"2019","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/30909226","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37171075","id":"PMC_37171075","title":"APOE expression and secretion are modulated by mitochondrial dysfunction.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/37171075","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30947667","id":"PMC_30947667","title":"Tanshinone IIA Promotes Macrophage Cholesterol Efflux and Attenuates Atherosclerosis of apoE-/- Mice by Omentin-1/ABCA1 Pathway.","date":"2019","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30947667","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39031528","id":"PMC_39031528","title":"Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference.","date":"2024","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/39031528","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26822228","id":"PMC_26822228","title":"THSD1 preserves vascular integrity and protects against intraplaque haemorrhaging in ApoE-/- mice.","date":"2016","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26822228","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35115575","id":"PMC_35115575","title":"APOE genetics influence murine gut microbiome.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35115575","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17244188","id":"PMC_17244188","title":"The missing ApoE allele.","date":"2007","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17244188","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20810111","id":"PMC_20810111","title":"Immune responses against aldehyde-modified laminin accelerate atherosclerosis in Apoe-/- mice.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/20810111","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36975090","id":"PMC_36975090","title":"APOE and immunity: Research highlights.","date":"2023","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/36975090","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21196212","id":"PMC_21196212","title":"The neurobiology of APOE in schizophrenia and mood disorders.","date":"2011","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/21196212","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31781638","id":"PMC_31781638","title":"Adipokine Chemerin Stimulates Progression of Atherosclerosis in ApoE-/- Mice.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31781638","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29075339","id":"PMC_29075339","title":"Berberine ameliorates non-alcoholic steatohepatitis in ApoE-/- mice.","date":"2017","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29075339","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30571174","id":"PMC_30571174","title":"Ablation of Myeloid ADK (Adenosine Kinase) Epigenetically Suppresses Atherosclerosis in ApoE-/- (Apolipoprotein E Deficient) Mice.","date":"2018","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30571174","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33991749","id":"PMC_33991749","title":"Myeloid cell-specific Irf5 deficiency stabilizes atherosclerotic plaques in Apoe-/- mice.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33991749","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"178903","id":"PMC_178903","title":"Simian virus 40-specific polypeptides in AD2+ ND1- and Ad2+ ND4-infected cells.","date":"1976","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/178903","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18415033","id":"PMC_18415033","title":"Regulated proteolysis of APP and ApoE receptors.","date":"2008","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/18415033","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32739681","id":"PMC_32739681","title":"Angiopoietin-like protein 8 accelerates atherosclerosis in ApoE-/- mice.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32739681","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34552216","id":"PMC_34552216","title":"Antiatherosclerotic effect of dehydrocorydaline on ApoE-/- mice: inhibition of macrophage inflammation.","date":"2021","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/34552216","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26051858","id":"PMC_26051858","title":"The leukotriene B4 receptor (BLT) antagonist BIIL284 decreases atherosclerosis in ApoE-/- mice.","date":"2015","source":"Prostaglandins & other lipid mediators","url":"https://pubmed.ncbi.nlm.nih.gov/26051858","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37051929","id":"PMC_37051929","title":"Contribution of APOE Genetic Variants to Dyslipidemia.","date":"2023","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37051929","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27856455","id":"PMC_27856455","title":"Map3k8 Modulates Monocyte State and Atherogenesis in ApoE-/- Mice.","date":"2016","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27856455","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26649902","id":"PMC_26649902","title":"SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/26649902","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31682994","id":"PMC_31682994","title":"Both gut microbiota and cytokines act to atherosclerosis in ApoE-/- mice.","date":"2019","source":"Microbial pathogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31682994","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33624733","id":"PMC_33624733","title":"Naringenin promotes cell autophagy to improve high-fat-diet-induced atherosclerosis in ApoE-/- mice.","date":"2021","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/33624733","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25843117","id":"PMC_25843117","title":"Chitosan Oligosaccharides Attenuate Atherosclerosis and Decrease Non-HDL in ApoE-/- Mice.","date":"2015","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/25843117","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28291794","id":"PMC_28291794","title":"Few serum proteins mediate APOE's association with dementia.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28291794","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18164902","id":"PMC_18164902","title":"Analyses of variants located in estrogen metabolism genes (ESR1, ESR2, COMT and APOE) and schizophrenia.","date":"2007","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/18164902","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36055579","id":"PMC_36055579","title":"Genetic disruption of the Gipr in Apoe-/- mice promotes atherosclerosis.","date":"2022","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36055579","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19058878","id":"PMC_19058878","title":"Amyloid precursor protein mediates monocyte adhesion in AD tissue and apoE(-)/(-) mice.","date":"2008","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/19058878","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32091078","id":"PMC_32091078","title":"Myriocin and d-PDMP ameliorate atherosclerosis in ApoE-/- mice via reducing lipid uptake and vascular inflammation.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/32091078","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34954030","id":"PMC_34954030","title":"Pharmacological inhibition of IRAK1 and IRAK4 prevents endothelial inflammation and atherosclerosis in ApoE-/- mice.","date":"2021","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/34954030","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27237075","id":"PMC_27237075","title":"TRAF3IP2 mediates atherosclerotic plaque development and vulnerability in ApoE(-/-) mice.","date":"2016","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/27237075","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27831589","id":"PMC_27831589","title":"The anti-inflammatory vasostatin-2 attenuates atherosclerosis in ApoE-/- mice and inhibits monocyte/macrophage recruitment.","date":"2016","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/27831589","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32762716","id":"PMC_32762716","title":"Atorvastatin promotes bone formation in aged apoE-/- mice through the Sirt1-Runx2 axis.","date":"2020","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/32762716","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32919187","id":"PMC_32919187","title":"Downregulation of G3BP2 reduces atherosclerotic lesions in ApoE-/- mice.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32919187","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38132357","id":"PMC_38132357","title":"The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer's Disease.","date":"2023","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38132357","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26005211","id":"PMC_26005211","title":"The association of apolipoprotein E (APOE) gene polymorphisms with atherosclerosis susceptibility: a meta-analysis.","date":"2015","source":"Minerva cardioangiologica","url":"https://pubmed.ncbi.nlm.nih.gov/26005211","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33907226","id":"PMC_33907226","title":"Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-/- mice.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33907226","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8346443","id":"PMC_8346443","title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.","date":"1993","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8346443","citation_count":7642,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3283935","id":"PMC_3283935","title":"Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.","date":"1988","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/3283935","citation_count":3529,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20686565","id":"PMC_20686565","title":"Biological, clinical and population relevance of 95 loci for blood lipids.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20686565","citation_count":2873,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23296339","id":"PMC_23296339","title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.","date":"2013","source":"Nature reviews. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23296339","citation_count":2574,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24097068","id":"PMC_24097068","title":"Discovery and refinement of loci associated with lipid levels.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24097068","citation_count":2409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11844848","id":"PMC_11844848","title":"Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.","date":"2002","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11844848","citation_count":2327,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19734902","id":"PMC_19734902","title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19734902","citation_count":2302,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28930663","id":"PMC_28930663","title":"The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.","date":"2017","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28930663","citation_count":2172,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19734903","id":"PMC_19734903","title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19734903","citation_count":2003,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11701639","id":"PMC_11701639","title":"Apolipoprotein E: far more than a lipid transport protein.","date":"2000","source":"Annual review of genomics and human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11701639","citation_count":1401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17192785","id":"PMC_17192785","title":"Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17192785","citation_count":1399,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19357304","id":"PMC_19357304","title":"Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19357304","citation_count":1392,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18193043","id":"PMC_18193043","title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18193043","citation_count":1310,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19679070","id":"PMC_19679070","title":"The role of apolipoprotein E in Alzheimer's disease.","date":"2009","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/19679070","citation_count":1218,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24816252","id":"PMC_24816252","title":"An atlas of genetic influences on human blood metabolites.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24816252","citation_count":1209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18193044","id":"PMC_18193044","title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18193044","citation_count":1130,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19060906","id":"PMC_19060906","title":"Common variants at 30 loci contribute to polygenic dyslipidemia.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19060906","citation_count":1113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20460622","id":"PMC_20460622","title":"Genome-wide analysis of genetic loci associated with Alzheimer disease.","date":"2010","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/20460622","citation_count":992,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28959956","id":"PMC_28959956","title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28959956","citation_count":964,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32376954","id":"PMC_32376954","title":"APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32376954","citation_count":943,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18583979","id":"PMC_18583979","title":"Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18583979","citation_count":817,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14688411","id":"PMC_14688411","title":"Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14688411","citation_count":781,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33340485","id":"PMC_33340485","title":"APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.","date":"2021","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33340485","citation_count":769,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29861287","id":"PMC_29861287","title":"APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types.","date":"2018","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/29861287","citation_count":764,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20186853","id":"PMC_20186853","title":"APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20186853","citation_count":724,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27477018","id":"PMC_27477018","title":"TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia.","date":"2016","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/27477018","citation_count":724,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54035,"output_tokens":3232,"usd":0.105292},"stage2":{"model":"claude-opus-4-6","input_tokens":6624,"output_tokens":2909,"usd":0.158768},"total_usd":0.629084,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":67564,"output_tokens":5059,"usd":0.139289},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8863,"output_tokens":4247,"usd":0.225735}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"ApoE isoforms regulate soluble Aβ metabolism by competing with Aβ for LRP1-dependent cellular uptake in astrocytes, rather than through direct extracellular binding to soluble Aβ in solution or CSF. Minimal apoE/soluble-Aβ association was detected in physiological conditions by multiple biochemical and analytical techniques.\",\n      \"method\": \"Brain Aβ microdialysis with apoE infusion, astrocyte uptake assays, multiple biochemical/analytical techniques for protein-protein interaction, cerebrospinal fluid analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (microdialysis, CSF analysis, cell uptake assays), single study with strong mechanistic resolution\",\n      \"pmids\": [\"23620513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ApoE directly inhibits the classical complement cascade (CCC) by high-affinity binding to activated C1q (KD ~140–580 pM), forming ApoE-C1q complexes that attenuate complement-driven inflammation. All three human ApoE isoforms share this activity.\",\n      \"method\": \"In vitro binding assays (KD measurement), immunofluorescence co-localization in human tissue, siRNA knockdown of C5 in mouse models, ApoE-deficient mouse studies\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct in vitro binding with KD measurement plus in vivo functional validation; replicated across human and mouse tissues\",\n      \"pmids\": [\"30692699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ApoE3 forms a complex with ABCA1 on the cell surface of normal fibroblasts; this interaction mediates ABCA1-dependent cholesterol efflux and generates nascent apoE-containing HDL-sized lipoprotein particles. Tangier disease mutation C1477R in ABCA1 abolishes both apoE3 binding and apoE-mediated cholesterol efflux.\",\n      \"method\": \"Radioligand competition binding assay (125I-apoA-I), cholesterol efflux assay, nascent particle analysis, ABCA1 mutant cell lines\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution with defined mutants, multiple complementary assays in single study\",\n      \"pmids\": [\"14754908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ApoE receptor-binding domain peptides (apoE(130-149) and apoE(141-155)2) bind directly to LRP1 extracellular domains (sLRPs 2, 3, and 4) with KD values in the 100 nM range, as determined by solution binding and surface plasmon resonance. Mutation Lys143Glu reduces binding 10-fold, identifying a key residue for LRP1 interaction.\",\n      \"method\": \"Surface plasmon resonance (SPR), solution binding assays, site-directed mutagenesis, heparin competition\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding measured by SPR with mutagenesis validation\",\n      \"pmids\": [\"15182176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"APOE accumulation in aged human mesenchymal progenitor cells drives cellular senescence by destabilizing heterochromatin: increased APOE leads to degradation of nuclear lamina proteins and the heterochromatin-associated protein KAP1 via the autophagy-lysosomal pathway. CRISPR-Cas9 deletion of APOE confers resistance to senescence.\",\n      \"method\": \"CRISPR-Cas9 knockout, human genetic aging models, stress-induced senescence models, autophagy-lysosomal pathway assays, Western blot, immunofluorescence\",\n      \"journal\": \"Nature aging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal models (genetic, stress-induced, physiological), loss-of-function with defined molecular pathway\",\n      \"pmids\": [\"37117743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ApoE3, but not apoE4, protects against excitotoxin-induced and age-dependent neurodegeneration in vivo. Neuronal expression of apoE3 preserved synaptophysin-positive presynaptic terminals, MAP2-positive dendrites, and neurofilament-positive axons following kainic acid challenge in apoE knockout mice.\",\n      \"method\": \"Transgenic mouse expression (neuron-specific enolase promoter), kainic acid excitotoxicity model, immunohistochemistry for synaptic and neuronal markers\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean isoform-specific rescue experiment in KO background with multiple neuronal readouts\",\n      \"pmids\": [\"10366621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Truncated apoE (22 kDa N-terminal fragment) and synthetic apoE peptides increase intracellular calcium and cause hippocampal neuron death through a cell surface receptor-dependent mechanism involving NMDA receptors; RAP (receptor-associated protein) and removal of extracellular calcium block these effects.\",\n      \"method\": \"Intracellular calcium imaging, embryonic rat hippocampal neuron culture, NMDA receptor antagonist (MK-801), receptor-associated protein (RAP) blocking, protease inhibitor studies\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of mechanism with multiple inhibitors, single lab\",\n      \"pmids\": [\"10436064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ApoE3 stimulates endothelial nitric oxide release in an isoform-dependent manner (apoE3 > apoE2 > apoE4), mediated by tyrosine phosphorylation of apoE receptor 2 (apoER2) and downstream PI3-kinase signaling.\",\n      \"method\": \"Fluorescent NO assay in cultured human EA.hy926 endothelial cells, PI3-kinase inhibitor treatment, apoER2 tyrosine phosphorylation analysis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, isoform comparison with pharmacological pathway dissection\",\n      \"pmids\": [\"12681505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Lipidated ApoE2 has impaired LDLR binding compared to lipApoE3/E4, which reduces LDLR recycling defects and decreases uptake of cholesteryl esters into neurons; ApoE4 > ApoE3 > ApoE2 confers lysosomal lipofuscinosis from polyunsaturated fatty acid-cholesteryl ester uptake. The protective Christchurch mutation phenocopies ApoE2 by also reducing LDLR binding.\",\n      \"method\": \"LDLR binding assays for lipidated apoE isoforms, LDLR recycling assays, human neuron CE uptake assays, intrahippocampal injection of PUFA-CE-lipApoE4 in mice, tau fibril lysosomal accumulation assay, APOE4 mouse brain analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal mechanistic assays in vitro and in vivo, isoform-specific and mutation-specific structure-function analysis\",\n      \"pmids\": [\"39532095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Mitochondrial dysfunction (genetic or pharmacological disruption of electron transport chain complexes I, III, or IV, or SLC25A transporter editing) upregulates APOE transcript, protein, and secretion up to 49-fold in diverse cell types and iPSC-derived human astrocytes, as part of an inflammatory gene expression program. Age- and genotype-dependent decline in respiratory complex I preceded APOE elevation in 5xFAD mice.\",\n      \"method\": \"Gene editing (SLC25A transporters), pharmacological ETC inhibition, iPSC-derived astrocytes, 5xFAD mouse model, transcriptomic analysis, APOE protein/secretion quantification\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological perturbations across diverse cell types with consistent results\",\n      \"pmids\": [\"37171075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ApoE receptors share processing machinery with APP: their cleavage at the cell surface by alpha-secretase activities is regulated by trafficking to/from the cell surface, and is modulated by extracellular matrix proteins (F-spondin, Reelin) and TIMP-3. ApoE receptors function in neuronal migration during development and in synaptic function in adults.\",\n      \"method\": \"Review integrating cell biological studies: trafficking assays, TIMP-3 regulation, receptor processing studies\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — review/synthesis paper, limited direct experimental evidence cited in abstract\",\n      \"pmids\": [\"18415033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Somatic gene transfer of human apoE into apoE-deficient/nude mice corrects the hypercholesterolemic phenotype within 14 days and leads to dose-dependent regression of established atherosclerotic fatty streak lesions, demonstrating that apoE expression is sufficient to normalize lipoprotein metabolism and reverse plaque burden.\",\n      \"method\": \"Adenoviral gene transfer in ApoE-deficient nude mice, cholesterol/triglyceride measurement, aortic lesion quantification\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean rescue experiment showing apoE sufficiency for lesion regression, single study\",\n      \"pmids\": [\"10669641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Lipid-associated ApoE4 preferentially binds to an intermediate aggregated form of Aβ and exhibits higher avidity than ApoE2 or ApoE3, with binding affinity dependent on the Aβ aggregation state.\",\n      \"method\": \"In vitro binding assay with various Aβ conformational states and lipid-associated ApoE isoforms\",\n      \"journal\": \"Sub-cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single binding assay, single lab, limited methodological detail in abstract\",\n      \"pmids\": [\"15709483\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ApoE is a multifunctional secreted lipoprotein that regulates lipid metabolism primarily through LRP1- and LDLR-mediated receptor uptake pathways; isoform-specific differences in LDLR binding (ApoE2 < ApoE3 < ApoE4) determine cholesteryl ester uptake and lysosomal pathology in neurons, while in astrocytes ApoE competes with Aβ for LRP1-dependent clearance rather than directly binding soluble Aβ; additionally, ApoE directly inhibits complement activation by high-affinity binding to C1q, interacts with ABCA1 to generate nascent HDL particles and mediate cholesterol efflux, triggers isoform-dependent NO production via apoER2/PI3K signaling in endothelial cells, and when accumulated intracellularly drives cellular senescence by destabilizing heterochromatin through autophagy-lysosomal degradation of nuclear lamina and KAP1.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"ApoE protein serves as a ligand for LDL receptors and participates in cholesterol and lipid transport among cells; a mutant form defective in LDL receptor binding causes familial type III hyperlipoproteinemia; ApoE is synthesized in liver, brain, spleen, and kidney and participates in cholesterol redistribution and repair responses to tissue injury.\",\n      \"method\": \"Biochemical characterization, receptor-binding assays, mutant analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — foundational biochemical work replicated extensively, multiple orthogonal methods\",\n      \"pmids\": [\"3283935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ApoE is a multifunctional protein whose three isoforms (E2, E3, E4) differ by single amino acid substitutions with profound functional consequences: apoE2 is associated with type III hyperlipoproteinemia; apoE4 increases risk for atherosclerosis and Alzheimer's disease, impairs neurite outgrowth, and reduces cognitive function; isoform-specific differences in cellular signaling exist.\",\n      \"method\": \"Isoform-specific functional assays, genetic studies, receptor-binding assays\",\n      \"journal\": \"Annual review of genomics and human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — strong preponderance of evidence across multiple labs and methods\",\n      \"pmids\": [\"11701639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ApoE peptides from the N-terminal receptor-binding domain (residues 130-149 and 141-155) bind directly to LRP1 (sLRP domains 2, 3, and 4) with KD values in the 100 nM range; mutation of Lys143 (but not Arg142) reduced binding 10-fold; both peptides also bind heparin, which competes for sLRP binding.\",\n      \"method\": \"Solution binding assays, surface plasmon resonance, mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted binding with SPR and mutagenesis in single rigorous study\",\n      \"pmids\": [\"15182176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ApoE3 forms a direct complex with ABCA1 in fibroblasts; lipid-free apoE3 inhibits apoA-I binding to ABCA1 (IC50 ~2.5 µg/ml vs 12.3 for reconstituted HDL); ABCA1 lipid translocase activity is required for biogenesis of apoE-containing HDL-sized particles; the ABCA1 Tangier disease mutation C1477R abolished apoE3 binding and apoE3-mediated cholesterol efflux; all apoE isoforms showed similar ABCA1 binding and cholesterol efflux kinetics.\",\n      \"method\": \"Radioligand competition binding, cholesterol efflux assay, native gel analysis, mutant ABCA1 fibroblasts\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, functional mutant validation\",\n      \"pmids\": [\"14754908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ApoE3, but not apoE4, protects against excitotoxin-induced and age-dependent neurodegeneration in mouse brain; neuronal expression of apoE3 preserved synaptophysin-positive terminals, MAP2-positive dendrites, and neurofilament-positive axons after kainic acid challenge, whereas apoE4 did not provide this protection.\",\n      \"method\": \"Transgenic mouse model (NSE-promoter driven human apoE3 or E4 in Apoe-/- background), immunohistochemistry, quantitative morphometry\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic model with isoform-specific comparison and multiple neuronal readouts\",\n      \"pmids\": [\"10366621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Truncated apoE (22 kDa N-terminal thrombin-cleavage fragment) and apoE-derived peptides cause intracellular calcium influx and hippocampal neuron death; these effects involve cell surface receptors and are reduced by receptor-associated protein (RAP) or NMDA receptor antagonist MK-801, and require extracellular calcium; protease inhibitors blocked full-length apoE toxicity but not truncated apoE toxicity, suggesting proteolytic fragments mediate apoE neurotoxicity.\",\n      \"method\": \"Primary neuron culture, calcium imaging, pharmacological inhibition (RAP, MK-801, calcium chelation), protease inhibitor treatment\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitor approaches, but mechanism not fully reconstituted\",\n      \"pmids\": [\"10436064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ApoE3 particles stimulate nitric oxide (NO) release from endothelial cells in an isoform-dependent manner (apoE3 > apoE2 > apoE4); this effect is mediated through tyrosine phosphorylation of apoE receptor 2 (apoER2) and downstream PI3-kinase signaling to activate NO synthase.\",\n      \"method\": \"Fluorescent NO assay in cultured endothelial cells, PI3-kinase inhibitor treatment, tyrosine phosphorylation analysis of apoER2\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional assay with pharmacological dissection, single lab\",\n      \"pmids\": [\"12681505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"When associated with lipid, apoE4 preferentially binds intermediate aggregated forms of Aβ with higher avidity than apoE2 or apoE3; different Aβ conformations during spontaneous aggregation confer differing binding affinities to the three apoE isoforms.\",\n      \"method\": \"In vitro binding assays with lipid-associated apoE isoforms and Aβ in various aggregation states\",\n      \"journal\": \"Sub-cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assay with isoform comparison, single study\",\n      \"pmids\": [\"15709483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ApoE and soluble Aβ interact minimally in solution and in human CSF; instead, apoE isoforms regulate sAβ metabolism in astrocytes and brain interstitial fluid by competing with Aβ for LRP1-dependent cellular uptake; this competition mechanism—not direct apoE/Aβ binding in extracellular fluids—accounts for apoE's regulation of Aβ clearance.\",\n      \"method\": \"Multiple biochemical and analytical techniques (size exclusion chromatography, native PAGE, ELISA), brain Aβ microdialysis in mice with apoE infusions, astrocyte uptake assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, in vitro and in vivo validation\",\n      \"pmids\": [\"23620513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The TREM2-APOE signaling pathway drives microglia from a homeostatic to a neurodegenerative phenotype in ALS, MS, and AD models; TREM2 induces APOE signaling after phagocytosis of apoptotic neurons; targeting the TREM2-APOE pathway restored homeostatic microglial signature and prevented neuronal loss; APOE-mediated neurodegenerative microglia lose tolerogenic function.\",\n      \"method\": \"Mouse models of ALS, MS, AD; single-cell transcriptomics; genetic manipulation (TREM2 KO, APOE KO); phagocytosis assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple disease models, genetic epistasis, replicated across conditions\",\n      \"pmids\": [\"28930663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ApoE4 exacerbates tau-mediated neurodegeneration independently of Aβ; P301S tau mice on an E4 background have higher brain tau levels, more somatodendritic tau redistribution, greater brain atrophy and neuroinflammation than E2, E3, or apoE-KO backgrounds; E4-expressing microglia have higher innate immune reactivity; co-culturing tau-expressing neurons with E4 glia causes more TNF-α secretion and reduced neuronal viability; apoE absence is protective.\",\n      \"method\": \"Human ApoE knock-in tau transgenic mice, immunohistochemistry, ELISA, neuron-glia co-culture, recombinant ApoE treatment\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models, in vitro and in vivo validation, isoform series\",\n      \"pmids\": [\"28959956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"APOE4 neurons show increased synapse number and elevated Aβ42 secretion; APOE4 astrocytes display impaired Aβ uptake and cholesterol accumulation; APOE4 microglia-like cells exhibit altered morphologies and reduced Aβ phagocytosis; converting APOE4 to APOE3 in sAD iPSC-derived brain cells attenuates multiple AD-related pathologies.\",\n      \"method\": \"CRISPR/Cas9 isogenic iPSC lines, transcriptional profiling, Aβ secretion/uptake assays, cholesterol measurement, phagocytosis assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — isogenic human cell system with multiple orthogonal functional assays\",\n      \"pmids\": [\"29861287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"All human ApoE isoforms attenuate classical complement cascade (CCC) activity via high-affinity binding to activated C1q protein (KD ~140-580 pM); C1q-ApoE complexes form in vivo at sites of complement activation including Aβ plaques, choroid plexus, and atherosclerotic arteries; ApoE-deficient mice show oxidized lipid-driven CCC activation and leukocyte infiltration; siRNA against C5 attenuated disease burden.\",\n      \"method\": \"In vitro binding assays (surface plasmon resonance/KD measurement), ApoE-deficient mouse model, siRNA knockdown, immunostaining of human tissues\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding measurement with KD, multiple disease models, in vivo validation\",\n      \"pmids\": [\"30692699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"APOE4 leads to blood-brain barrier (BBB) breakdown in the hippocampus and medial temporal lobe independently of Aβ or tau pathology; this is associated with increased activity of the cyclophilin A-MMP9 pathway; CSF levels of soluble PDGFRβ (pericyte injury biomarker) predicted future cognitive decline in APOE4 carriers.\",\n      \"method\": \"Dynamic contrast-enhanced MRI for BBB permeability, CSF biomarkers (PDGFRβ, cyclophilin A, MMP9), PET amyloid/tau imaging in human subjects\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct BBB permeability measurement, mechanistic pathway identified, prospective cognitive outcome\",\n      \"pmids\": [\"32376954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TREM2 binds directly to APOE (and CLU/APOJ) as identified by unbiased protein microarray screen; binding of apolipoproteins by TREM2 was abolished or reduced by AD-associated TREM2 mutations; TREM2 overexpression enhanced cellular uptake of APOE; Trem2 knockout microglia showed reduced internalization; Aβ bound to APOE is taken up by microglia in a TREM2-dependent fashion.\",\n      \"method\": \"Protein microarray screen, Co-IP, overexpression and KO cellular assays, human macrophages from TREM2 variant carriers\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased screen validated by multiple functional assays, human genetic validation\",\n      \"pmids\": [\"27477018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Increased APOE expression in aged human mesenchymal progenitor cells (MPCs) drives cellular senescence; CRISPR-Cas9 deletion of APOE confers resistance to senescence; mechanistically, excess APOE promotes degradation of nuclear lamina proteins and the heterochromatin-associated protein KAP1 via the autophagy-lysosomal pathway, thereby destabilizing heterochromatin.\",\n      \"method\": \"Human cellular aging models, CRISPR-Cas9 KO, Western blot, autophagy-lysosomal pathway inhibitors, chromatin analysis\",\n      \"journal\": \"Nature aging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with mechanistic pathway dissection, multiple aging models\",\n      \"pmids\": [\"37117743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Mitochondrial dysfunction (genetic or pharmacological disruption of ETC complexes I, III, or IV, or SLC25A transporters) causes up to 49-fold upregulation of APOE transcript, protein, and secretion as part of an inflammatory gene expression program; this was demonstrated across diverse cell types including iPSC-derived human astrocytes; age- and genotype-dependent decline in complex I preceded APOE increases in 5xFAD mouse brain.\",\n      \"method\": \"Gene editing of ETC components, pharmacological ETC inhibitors, iPSC-derived astrocytes, transcriptomics, ELISA, 5xFAD mouse brain analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological perturbations, diverse cell types, in vivo validation\",\n      \"pmids\": [\"37171075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Lipidated ApoE2 (lipApoE2) has impaired LDLR binding compared to lipApoE3/E4, which avoids LDLR recycling defects and decreases uptake of cholesteryl esters (CEs) linked to neurodegeneration; in human neurons, ApoE carrying polyunsaturated fatty acid-CEs causes lipofuscinosis in an allelic series (E4 > E3 > E2); lipofuscin increases lysosomal tau fibril accumulation; intrahippocampal injection of PUFA-CE-lipApoE4 induces lipofuscinosis; the protective Christchurch mutation also reduces LDLR binding, phenocopying ApoE2.\",\n      \"method\": \"iPSC-derived human neurons, LDLR binding assays, lipofuscin quantification, tau fibril uptake assays, intrahippocampal injection in mice, APOE4 mouse brain analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic reconstitution in human neurons, in vivo injection, multiple orthogonal approaches\",\n      \"pmids\": [\"39532095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"APP and apoE receptors share extracellular-binding partners (F-spondin, Reelin) that promote their cell surface presence; both APP and apoE receptors are cleaved at the cell surface by alpha-secretase; their processing is regulated by TIMP-3; endothelial APP phosphorylated at Tyr682 associates with Src tyrosine kinase in apoE-/- and AD brains, and APP mediates monocyte adhesion to brain endothelium.\",\n      \"method\": \"Immunohistochemistry, Western blot, co-immunoprecipitation (APP-Src), modified Stamper-Woodruff adhesion assay\",\n      \"journal\": \"Molecular neurobiology / Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP and functional adhesion assay, single lab\",\n      \"pmids\": [\"18415033\", \"19058878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The full-length two-domain structure of apoE3 was characterized and shown to support communication between the N-terminal and C-terminal domains; a single amino acid difference (Cys112→Arg) between apoE3 and apoE4 propagates structural changes from the N-terminal domain through to the C-terminal domain.\",\n      \"method\": \"Structural analysis and biophysical characterization of recombinant apoE protein\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — structural characterization, but limited functional mutational validation in this paper\",\n      \"pmids\": [\"24115173\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ApoE is a secreted lipoprotein-associated protein that functions as an LDL receptor ligand for cholesterol/lipid transport; its three isoforms (E2, E3, E4) differ by single amino acid substitutions that produce isoform-specific differences in LDLR/LRP1 binding, ABCA1-mediated lipoprotein particle formation, complement C1q inhibition, endothelial NO signaling via apoER2/PI3K, and in the brain: regulation of Aβ clearance through LRP1 competition, direct TREM2 binding to facilitate microglial Aβ/lipoprotein uptake, tau pathology exacerbation via microglial neuroinflammation, blood-brain barrier integrity through pericyte/cyclophilin A-MMP9 signaling, heterochromatin destabilization driving cellular senescence via autophagy-lysosomal degradation of KAP1 and lamins, endolysosomal lipid pathology through LDLR-mediated cholesteryl ester uptake, and upstream regulation by mitochondrial electron transport chain dysfunction.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ApoE is a secreted apolipoprotein that serves as a central regulator of lipid transport, innate immune modulation, and neuronal homeostasis through isoform-dependent interactions with lipoprotein receptors. It binds LDLR and LRP1 via its receptor-binding domain (residues ~130–155, with Lys143 critical for LRP1 engagement), and isoform-specific differences in LDLR affinity (ApoE2 < ApoE3 < ApoE4) determine cholesteryl ester uptake, LDLR recycling, and susceptibility to neuronal lysosomal lipofuscinosis [PMID:39532095, PMID:15182176]; in astrocytes, ApoE competes with Aβ for LRP1-dependent clearance rather than binding soluble Aβ directly [PMID:23620513]. ApoE interacts with ABCA1 to generate nascent HDL particles and mediate cholesterol efflux [PMID:14754908], directly inhibits the classical complement cascade by high-affinity binding to C1q (KD ~140–580 pM) [PMID:30692699], and triggers isoform-dependent endothelial NO production through apoER2/PI3K signaling [PMID:12681505]. Intracellular accumulation of ApoE in aged progenitor cells drives cellular senescence by promoting autophagy-lysosomal degradation of nuclear lamina proteins and the heterochromatin factor KAP1, destabilizing heterochromatin; CRISPR deletion of APOE confers senescence resistance [PMID:37117743].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"ApoE's neuroprotective role was shown to be isoform-specific, establishing that ApoE3 — but not ApoE4 — is sufficient to prevent excitotoxic and age-dependent neurodegeneration when expressed in neurons.\",\n      \"evidence\": \"Neuron-specific transgenic expression in apoE-KO mice with kainic acid challenge and immunohistochemical assessment of synaptic/dendritic/axonal markers\",\n      \"pmids\": [\"10366621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of isoform-specific neuroprotection not defined at molecular level\", \"Whether astrocyte-derived versus neuron-derived apoE differs functionally was not tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Truncated apoE fragments were shown to be neurotoxic via a receptor-mediated mechanism involving NMDA receptor-dependent calcium influx, revealing that apoE proteolysis products can be gain-of-function pathological species.\",\n      \"evidence\": \"Calcium imaging and cell death assays in embryonic rat hippocampal neurons with RAP blocking and NMDA receptor antagonism\",\n      \"pmids\": [\"10436064\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the specific apoE receptor mediating toxicity was not established\", \"Relevance of the 22 kDa fragment in vivo not demonstrated\", \"Single lab without independent replication\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"ApoE gene transfer was demonstrated to be sufficient to correct hypercholesterolemia and regress atherosclerotic lesions in apoE-deficient mice, establishing ApoE as functionally sufficient for lipoprotein metabolism normalization.\",\n      \"evidence\": \"Adenoviral human APOE delivery in apoE-KO nude mice with plasma lipid and aortic lesion quantification\",\n      \"pmids\": [\"10669641\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Long-term durability of gene-transfer correction not assessed\", \"Isoform-specific effects on lesion regression not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"ApoE was shown to activate endothelial nitric oxide signaling in an isoform-dependent manner (E3>E2>E4) through apoER2 tyrosine phosphorylation and PI3K, linking apoE to vascular tone regulation.\",\n      \"evidence\": \"Fluorescent NO assay and apoER2 phosphorylation analysis in human endothelial cells with PI3K inhibitor\",\n      \"pmids\": [\"12681505\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo vascular consequences of isoform-specific NO differences not tested\", \"Downstream mediators between PI3K and eNOS not mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The molecular basis of ApoE's two primary receptor interactions was defined: direct binding to LRP1 via the 130–155 receptor-binding domain (KD ~100 nM, Lys143-dependent) and a functionally distinct interaction with ABCA1 mediating cholesterol efflux and nascent HDL biogenesis.\",\n      \"evidence\": \"SPR and solution binding with site-directed mutagenesis for LRP1; radioligand competition binding, cholesterol efflux, and Tangier disease mutant analysis for ABCA1\",\n      \"pmids\": [\"15182176\", \"14754908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LRP1 and ABCA1 interactions occur simultaneously on the same particle was not tested\", \"Structural basis of the apoE–ABCA1 complex not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A key question in Alzheimer's disease biology — whether ApoE clears Aβ by direct binding or by competition — was resolved: ApoE competes with Aβ for LRP1-mediated uptake in astrocytes rather than forming stable extracellular apoE–Aβ complexes.\",\n      \"evidence\": \"Brain Aβ microdialysis with apoE infusion, astrocyte uptake assays, multiple biochemical interaction analyses, and CSF examination\",\n      \"pmids\": [\"23620513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this competitive mechanism operates identically in microglia or neurons was not established\", \"Impact of lipidation state on the competition not fully defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"ApoE was discovered to function as a direct inhibitor of the classical complement cascade through high-affinity binding to activated C1q, extending its role beyond lipid metabolism to innate immune regulation.\",\n      \"evidence\": \"In vitro KD measurements (~140–580 pM), co-localization in human tissue, C5 siRNA and apoE-KO mouse functional studies\",\n      \"pmids\": [\"30692699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether isoform-specific differences affect complement inhibition in vivo not resolved\", \"Structural determinants of the apoE–C1q interaction not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"An unexpected intracellular role for ApoE was established: accumulated APOE drives cellular senescence by triggering autophagy-lysosomal degradation of nuclear lamina and KAP1, destabilizing heterochromatin — a mechanism linking ApoE to aging independent of its extracellular lipoprotein functions.\",\n      \"evidence\": \"CRISPR-Cas9 APOE knockout, human genetic and stress-induced senescence models, autophagy-lysosomal pathway analysis\",\n      \"pmids\": [\"37117743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this senescence mechanism is isoform-specific was not determined\", \"How intracellular ApoE engages the autophagy-lysosomal machinery to target lamina/KAP1 is not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"APOE was identified as a stress-responsive gene massively upregulated (up to 49-fold) by mitochondrial dysfunction, positioning it as a component of an inflammatory transcriptional program triggered by respiratory chain impairment.\",\n      \"evidence\": \"Gene editing of SLC25A transporters, pharmacological ETC inhibition, iPSC-derived astrocytes, 5xFAD mouse model transcriptomics\",\n      \"pmids\": [\"37171075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether APOE upregulation is protective or pathogenic in the context of mitochondrial dysfunction is unclear\", \"Transcription factors mediating APOE induction by ETC stress not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The long-standing question of how ApoE isoforms differentially affect neuronal lipid pathology was mechanistically resolved: graded LDLR binding affinity (E4>E3>E2) determines receptor recycling efficiency and cholesteryl ester uptake, with stronger binding driving lysosomal lipofuscinosis; the protective Christchurch mutation phenocopies ApoE2's weak LDLR binding.\",\n      \"evidence\": \"LDLR binding and recycling assays, human neuron CE uptake, intrahippocampal PUFA-CE-lipApoE4 injection in mice, Christchurch mutation structure-function analysis\",\n      \"pmids\": [\"39532095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether therapeutic reduction of apoE4–LDLR binding affinity is sufficient to prevent neurodegeneration in humans remains untested\", \"Contribution of other apoE receptors (e.g., LRP1) to the lysosomal phenotype not dissected\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of ApoE's interaction with C1q, the mechanism by which intracellular ApoE selectively targets nuclear lamina and KAP1 for autophagy-lysosomal degradation, and whether the senescence and complement functions are isoform-specific in vivo remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Structural model of apoE–C1q complex not available\", \"How intracellular ApoE engages autophagy machinery is undefined\", \"Isoform-specific effects on senescence and complement inhibition in vivo not tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 8, 11]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 0]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [7, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 2, 8, 11]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [4, 8]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 8, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [4, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LRP1\", \"LDLR\", \"ABCA1\", \"C1Q\", \"APOER2\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Apolipoprotein E is a secreted lipid-transport protein that serves as a high-affinity ligand for the LDL receptor family (LDLR, LRP1, apoER2), mediating cellular cholesterol uptake and redistribution, and whose three common isoforms (E2, E3, E4) differ by single amino acid substitutions that profoundly alter receptor-binding affinity, lipoprotein particle formation via ABCA1, and disease risk [PMID:3283935, PMID:11701639, PMID:14754908]. In the brain, ApoE regulates amyloid-β clearance by competing with Aβ for LRP1-dependent uptake, serves as a direct ligand for the microglial receptor TREM2 to facilitate Aβ/lipoprotein phagocytosis, and exacerbates tau-mediated neurodegeneration through isoform-dependent microglial neuroinflammation, with ApoE4 consistently conferring the greatest pathological burden [PMID:23620513, PMID:27477018, PMID:28930663, PMID:29861287, PMID:28959956]. ApoE4 also disrupts blood–brain barrier integrity through the cyclophilin A–MMP9 pericyte-injury pathway, promotes endolysosomal lipofuscinosis via LDLR-mediated uptake of polyunsaturated fatty acid–cholesteryl esters that enhance lysosomal tau fibril accumulation, and attenuates classical complement activation through picomolar-affinity binding to activated C1q [PMID:32376954, PMID:39532095, PMID:30692699]. Beyond neurodegeneration, elevated APOE expression driven by mitochondrial electron-transport-chain dysfunction promotes cellular senescence by triggering autophagy-lysosomal degradation of nuclear lamina proteins and heterochromatin factor KAP1 [PMID:37117743, PMID:37171075].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing ApoE as an LDL receptor ligand central to lipid transport resolved its core molecular function and linked receptor-binding-defective mutations to familial type III hyperlipoproteinemia.\",\n      \"evidence\": \"Biochemical receptor-binding assays and mutant analysis in multiple tissues\",\n      \"pmids\": [\"3283935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of receptor recognition not yet defined\",\n        \"Brain-specific functions uncharacterized\",\n        \"Isoform-specific functional consequences not yet delineated\"\n      ]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstration that ApoE3, but not ApoE4, protects neurons against excitotoxic and age-dependent neurodegeneration established isoform-specific neuroprotective functions independent of peripheral lipid metabolism.\",\n      \"evidence\": \"Human apoE isoform knock-in transgenic mice challenged with kainic acid, quantitative morphometry of synapses and dendrites\",\n      \"pmids\": [\"10366621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Downstream signaling pathway mediating neuroprotection unknown\",\n        \"Whether truncated apoE fragments contribute to neurotoxicity in vivo not settled\",\n        \"Mechanism by which E4 fails to protect not defined\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Comprehensive functional characterization of all three isoforms consolidated the framework that single amino acid changes (Cys112Arg, Arg158Cys) produce divergent effects on receptor binding, neurite outgrowth, and disease susceptibility.\",\n      \"evidence\": \"Isoform-specific functional assays, genetic association studies, receptor-binding assays across multiple labs\",\n      \"pmids\": [\"11701639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Atomic-level structural basis for isoform-specific domain interactions unresolved\",\n        \"Isoform-specific signaling cascades not mapped\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mapping the LRP1-binding epitope to ApoE residues 130–155 with nanomolar affinity and identifying Lys143 as critical resolved the structural requirements for receptor engagement and heparin competition.\",\n      \"evidence\": \"Surface plasmon resonance, solution binding assays, and site-directed mutagenesis with soluble LRP domains\",\n      \"pmids\": [\"15182176\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full-length ApoE–LRP1 co-structure not available\",\n        \"Relative contribution of LRP1 vs LDLR binding in brain Aβ clearance unknown\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Discovery that ApoE forms a direct complex with ABCA1 and requires ABCA1 lipid translocase activity for HDL-sized particle biogenesis established the mechanism by which ApoE acquires lipid for functional lipoprotein assembly.\",\n      \"evidence\": \"Radioligand competition binding, native gel analysis, cholesterol efflux assay, and Tangier disease mutant ABCA1 fibroblasts\",\n      \"pmids\": [\"14754908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Stoichiometry and structure of ApoE–ABCA1 complex not defined\",\n        \"Whether ABCA1-dependent lipidation differs by isoform in vivo uncertain\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that ApoE regulates brain Aβ clearance by competing with Aβ for LRP1-dependent uptake—rather than through direct ApoE–Aβ complexes in extracellular fluid—fundamentally reframed the mechanism of ApoE's role in amyloid pathology.\",\n      \"evidence\": \"Brain microdialysis with apoE infusions in vivo, astrocyte uptake assays, size-exclusion chromatography of CSF\",\n      \"pmids\": [\"23620513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether competition mechanism operates equivalently across all brain regions not tested\",\n        \"Quantitative contribution of astrocytes vs microglia to Aβ clearance in this model unclear\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Structural characterization of full-length apoE3 revealed inter-domain communication such that the single Cys112→Arg change in apoE4 propagates conformational changes to the C-terminal domain, providing a physical basis for isoform-specific differences.\",\n      \"evidence\": \"Biophysical characterization of recombinant full-length apoE protein\",\n      \"pmids\": [\"24115173\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"High-resolution co-crystal with receptors not obtained\",\n        \"Functional validation of proposed domain–domain interaction limited\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of TREM2 as a direct ApoE receptor on microglia—with AD-associated TREM2 mutations impairing binding—established a new axis linking ApoE to microglial phagocytic function and innate immunity in neurodegenerative disease.\",\n      \"evidence\": \"Unbiased protein microarray screen, co-IP, TREM2 KO and overexpression cellular assays, human TREM2-variant macrophages\",\n      \"pmids\": [\"27477018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"ApoE–TREM2 binding interface not structurally resolved\",\n        \"Relative contribution of TREM2-dependent vs LRP1-dependent uptake in microglia not quantified\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linking the TREM2–APOE axis to a transcriptional switch from homeostatic to neurodegenerative microglial states across ALS, MS, and AD models generalized ApoE's role in microglial polarization beyond Alzheimer's disease.\",\n      \"evidence\": \"Single-cell transcriptomics in multiple mouse disease models, TREM2 KO and APOE KO genetic epistasis, phagocytosis assays\",\n      \"pmids\": [\"28930663\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether restoring homeostatic microglial state is therapeutic in humans unknown\",\n        \"Whether ApoE isoforms differentially drive this transcriptional switch not tested in this study\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that ApoE4 exacerbates tau-mediated neurodegeneration independently of Aβ—through enhanced microglial inflammatory reactivity—decoupled ApoE's pathogenic effects from the amyloid cascade.\",\n      \"evidence\": \"Human ApoE knock-in × P301S tau transgenic mice, neuron-glia co-culture with isoform-specific glia, TNF-α measurement\",\n      \"pmids\": [\"28959956\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular mechanism by which ApoE4 enhances microglial TNF-α production not defined\",\n        \"Whether ApoE absence is protective in human tauopathy unknown\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Using isogenic iPSC-derived neurons, astrocytes, and microglia confirmed cell-type-specific ApoE4 pathologies (increased Aβ secretion, impaired Aβ uptake, cholesterol accumulation) in human cells and showed that CRISPR correction of E4 to E3 rescues these phenotypes.\",\n      \"evidence\": \"CRISPR/Cas9 isogenic iPSC lines, transcriptional profiling, Aβ secretion/uptake assays, cholesterol measurement, phagocytosis assays\",\n      \"pmids\": [\"29861287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether E4→E3 correction rescues in vivo brain pathology in humanized models not shown\",\n        \"Mechanism by which E4 increases neuronal synapse number unclear\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that all ApoE isoforms bind activated C1q with picomolar affinity and attenuate classical complement cascade activation revealed a previously unrecognized immunomodulatory function of ApoE in both brain and vasculature.\",\n      \"evidence\": \"Surface plasmon resonance (KD ~140–580 pM), immunostaining of human Aβ plaques and atherosclerotic arteries, ApoE-KO mice with C5 siRNA rescue\",\n      \"pmids\": [\"30692699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether isoform differences in C1q binding affinity are functionally significant in vivo not resolved\",\n        \"Structural basis of ApoE–C1q interaction unknown\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that APOE4 causes blood–brain barrier breakdown via the cyclophilin A–MMP9 pericyte pathway independently of Aβ/tau established a vascular mechanism for ApoE4-associated cognitive decline.\",\n      \"evidence\": \"Dynamic contrast-enhanced MRI for BBB permeability, CSF pericyte-injury biomarkers, PET amyloid/tau imaging in human subjects\",\n      \"pmids\": [\"32376954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct causal link between pericyte CypA–MMP9 and BBB permeability in humans not interventionally tested\",\n        \"Whether BBB breakdown is reversible with CypA inhibition in E4 carriers unknown\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing that elevated APOE drives cellular senescence by promoting autophagy-lysosomal degradation of nuclear lamins and KAP1, destabilizing heterochromatin, extended ApoE's functional repertoire to chromatin regulation and aging.\",\n      \"evidence\": \"CRISPR-Cas9 APOE KO in human mesenchymal progenitor cells, autophagy-lysosomal pathway inhibitors, Western blot, chromatin analysis\",\n      \"pmids\": [\"37117743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether this senescence mechanism operates in neurons or astrocytes not tested\",\n        \"How APOE protein triggers autophagy-lysosomal degradation of nuclear lamina components mechanistically unclear\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of mitochondrial ETC dysfunction as a potent upstream driver of APOE transcriptional upregulation connected metabolic stress to ApoE-mediated inflammatory and neurodegenerative pathways.\",\n      \"evidence\": \"Gene editing and pharmacological inhibition of ETC complexes I/III/IV, iPSC-derived astrocytes, transcriptomics, 5xFAD mouse brain analysis\",\n      \"pmids\": [\"37171075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Transcription factors and cis-regulatory elements mediating ETC-dependent APOE induction not identified\",\n        \"Whether ETC dysfunction-driven APOE increase is sufficient to trigger downstream Aβ or senescence phenotypes not shown\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Reconstituting ApoE isoform- and LDLR-dependent endolysosomal lipofuscinosis in human neurons—showing that PUFA-cholesteryl ester-loaded ApoE4 particles cause lipofuscin accumulation that enhances tau fibril retention—unified lipid metabolism and tau pathology in a single endolysosomal mechanism.\",\n      \"evidence\": \"iPSC-derived neurons, LDLR binding assays, lipofuscin quantification, tau fibril uptake, intrahippocampal injection in mice, Christchurch mutation analysis\",\n      \"pmids\": [\"39532095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether lipofuscinosis pathway is reversible or druggable not tested\",\n        \"Relative contribution of LDLR vs LRP1 in neuronal lipofuscin accumulation not dissected\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full structural basis of ApoE isoform–receptor complexes, whether therapeutic modulation of TREM2–ApoE or CypA–MMP9 pathways can reverse ApoE4-driven pathology in humans, and the transcriptional mechanism linking mitochondrial dysfunction to APOE upregulation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No high-resolution co-crystal structure of ApoE with any receptor\",\n        \"No interventional human trial targeting ApoE-specific pathogenic mechanisms\",\n        \"Transcriptional regulation of APOE by mitochondrial stress not mechanistically dissected\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 3, 7, 17]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 2, 6, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 12, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 8, 12, 17]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [15, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 3, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 10, 12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 10, 11, 13, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 9, 14]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [15, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"LDLR\",\n      \"LRP1\",\n      \"ABCA1\",\n      \"TREM2\",\n      \"C1Q\",\n      \"LRP8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}